Disclosures: Barbara Coco: Nothing to Disclose, Lamia Ait Al: Nothing to Disclose, Lorenzo De Stefano: Nothing to Disclose, Giovanni Petralli: Nothing to Disclose, Ferruccio Bonino: Nothing to Disclose, Pierluigi Festa: Nothing to Disclose, Maurizia Brunetto: Nothing to Disclose 586 A FIRST-IN-CLASS TOOL TO PREDICT FUTURE RISK OF PORTAL HYPERTENSION, LIVER TRANSPLANT AND DEATH IN CHILDREN WITH ALPHA-1-ANTITRYPSIN DEFICIENCY BASED ON PROSPECTIVE DATA FROM THE CHILDHOOD LIVER DISEASE RESEARCH NETWORK Jeffrey Teckman 1 Catherine Spino 2 Suiyan Huang 2 Gregor Horvath 2 John Magee 3 Philip Rosenthal 4 , 1 Saint Louis University, 2 University of Michigan Hospital, 3 University of Michigan Hospitals and Health Centers, 4 University of California, San Francisco Background: Children with homozygous ZZ and SZ Alpha-1-antitrypsin deficiency (AATD) exhibit a wide range of liver disease outcomes from asymptomatic without fibrosis to portal hypertension progressing to transplant or death
Your prescriber will review your past medical history when prescribing Semaglutide to check it is suitable for you
(dba Chuck E
Patients were excluded if they had any other chronic liver disease other than MASLD/MASH including alcohol, viral, drug-induced, autoimmune, Budd-Chiari syndrome, Wilsons disease, alpha-1-antitrypsin deficiency, hereditary hemochromatosis, primary/secondary biliary cholangitis, primary sclerosing cholangitis, liver disorders in diseases classified elsewhere, and other chronic hepatitis not classified elsewhere
